- AMAG Pharmaceuticals (NASDAQ:AMAG) slumps 11% premarket on average volume in response to its announcement of preliminary Q4 and full-year results and guidance for 2017.
- Q4: revenues: $149M - 154M versus consensus of $154.9M. Makena sales: $96M - 99M.
- 2016 revenues: $529M - 551M versus consensus of $551.3M.
- 2017 guidance: revenues: $620M - 670M; operating income: $103M - 173M; net income: $19M - 60M.
- #JPM17